TORONTO, ON / ACCESSWIRE / August 14, 2020 / StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS) today announced that it will release its Second Quarter 2020 operational results after market close on Friday, August 14, 2020. StageZero’s Chairman and CEO, James R Howard-Tripp, will host a conference call and online presentation at 8:30 am ET on Monday August 17th to review the operational results and discuss business developments for the period and to date.
Analyst and Investor Call
Event Date: Monday August 17, 2020
Time: 8:30 AM EST
Webcast Link: https://www.webcaster4.com/Webcast/Page/2082/36633
Participant Numbers:
Toll Free: 844-369-8770
International: 862-298-0840
Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 36633
About StageZero Life Sciences, Ltd.
StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (live virus) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. As we provide COVID-19 test during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. www.stagezerolifesciences.com
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as “expects”, “will” and similar expressions, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company’s actual events to differ materially from those projected herein. Investors should consult the Company’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Company Contacts:
James R. Howard-Tripp
Chairman & CEO
jht@stagezerols.com
Tel: 1-855-420-7140 Ext. 1
Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838
SOURCE: StageZero Life Sciences Ltd
View source version on accesswire.com:
https://www.accesswire.com/601746/StageZero-Announces-Second-Quarter-Analyst-and-Investor-Call
Received FDA Clearance for the HeartBeam System – an At-Home, High-Fidelity Heart Monitoring Technology Commenced…
Shareholders reelect all 12 members to board of directors during annual general meeting GALWAY, Ireland,…
COCONUT GROVE, Fla., March 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or…
SUNNYVALE, Calif., March 13, 2025 /PRNewswire/ -- Imagine finishing your last appointment of the day and…
In the wake of the recent Change Healthcare/UHC data breach, critical vulnerabilities in healthcare have…
The Company will use proceeds to further innovate its care-at-home services, software, and technology to…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
